IC

ArriVent BioPharma, Inc. (AVBP)

NASDAQ: AVBP · Real-Time Price · USD

19.99

-0.16 (-0.79%)

At close: May 12, 2025, 4:00 PM

20.50

+0.51 (2.55%)

After-hours: May 12, 2025, 4:24 PM EDT

ArriVent BioPharma Employees

ArriVent BioPharma had 52 employees as of December 31, 2024. The number of employees increased by 12 or 30.00% compared to the previous year.

Employees

52

Change (1Y)

12

Growth (1Y)

30.00%

Revenue / Employee

n/a

Profits / Employee

-$2,451,115

Market Cap

680.56M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	52	12	30.00%
Dec 31, 2023	40	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	94,300
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

AVBP News

16 hours ago - ArriVent BioPharma Reports First Quarter 2025 Financial Results - GlobeNewsWire
14 days ago - ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors - GlobeNewsWire
2 months ago - ArriVent BioPharma Reports Full Year 2024 Financial Results - GlobeNewsWire
3 months ago - ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers - GlobeNewsWire
8 months ago - ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer - GlobeNewsWire
9 months ago - Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma - Business Wire
9 months ago - ArriVent BioPharma Reports Second Quarter 2024 Financial Results - GlobeNewsWire
9 months ago - ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer - GlobeNewsWire